Norman Tse

Norman Tse, CFA, is a highly experienced finance professional with a focus on healthcare investments. Currently serving as Vice President at Unicorn Capital Partners since June 2022, Norman manages healthcare funds and direct investments. Additional roles include being an investor for Bluejay Therapeutics and ArriVent Biopharma, as well as a panelist for the Biotechnology Subgroup of the Innovation and Technology Commission under the HKSAR Government. Norman's previous experience includes key positions at Pivotal Life Sciences, where management of direct and fund investments was emphasized, and board observer roles at multiple companies. Norman holds a Master of Translational Medicine from the University of California, Berkeley and the University of California, San Francisco, alongside a Bachelor of Science in Biochemistry from The University of Hong Kong.